Your patients count on you. You can count on us
100% of prescriptions cost patients less than $50 with most patients paying less than $10
*Based on IQVIA claims data from 01/2020 through 12/2020 using commercial, health exchange, Medicare and Medicaid claims.
†Percentage is based upon claims data including those where copay card was used.
‡Patient out-of-pocket costs can vary throughout the year depending on which phase of the Part D benefit they are currently in. Medicare Part D drug coverage is divided into 4 phases, each with a different cost-sharing amount. Those phases are 1) Deductible, 2) Initial coverage, 3) Coverage gap, 4) Catastrophic.
A virtual Repatha® Access Specialist (RAS) who understands coverage in your region is available when you need assistance.
Contact your Virtual RAS for questions about access topics such as:
For Virtual RAS support,
Monday through Friday,
8AM to 8PM ET.
Virtual RAS Information Card
Access Repatha® coverage information, prior authorization (PA) requirements, health plan PA forms, and more.
Repatha® Copay Card reduces costs for Repatha® for eligible commercially insured patients.
CoverMyMeds®: offers electronic prior authorization submission
CoverMyMeds® electronically connects providers, pharmacists, and health plans
Visit CoverMyMeds to learn more.
Learn more details about the CoverMyMeds Program in this brochure
Serving patients in need™
The Amgen Safety Net Foundation (ASNF) helps patients with financial need gain access to Amgen medicines at no cost.
Click here to see if your patient is eligible.
Reference: 1. Data on file, Amgen; 2021.
Repatha® is indicated:
Contraindication: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.
Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha®. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.
Adverse Reactions in Primary Hyperlipidemia: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.
From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. Hypersensitivity reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common hypersensitivity reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).
Adverse Reactions in the Cardiovascular Outcomes Trial: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo).
Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes mellitus during the trial was 8.1% in patients treated with Repatha® compared with 7.7% in patients that received placebo.
Immunogenicity: Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with Repatha®.
Please see full Prescribing Information.